- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
MDxHealth SA ADR (MDXH)
Track the MDxHealth ADR share price today and view real-time MDXH share price data, including charts, technicals, and key financials. View the MDXH premarket stock price ahead of the market session or assess the after hours quote. Explore MDXH stock price movements, trading volume, and market activity across the NASDAQ exchange.
What Is the MDxHealth ADR Stock Price Today?
The MDxHealth ADR stock price today is 0.462.
What Is the Stock Symbol for MDxHealth ADR?
The stock symbol for MDxHealth ADR is ""MDXH.""
What Stock Exchange Does MDxHealth ADR Trade On?
MDxHealth ADR is listed and trades on the NASDAQ stock exchange.
Is MDxHealth ADR a Good Stock to Buy?
Determining whether MDxHealth ADR or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MDXH quote. (ISIN: BE0974461940)
What Is the MDxHealth ADR Stock Price Today?
The MDxHealth ADR stock price today is 0.462.
What Is the Stock Symbol for MDxHealth ADR?
The stock symbol for MDxHealth ADR is ""MDXH.""
What Stock Exchange Does MDxHealth ADR Trade On?
MDxHealth ADR is listed and trades on the NASDAQ stock exchange.
Is MDxHealth ADR a Good Stock to Buy?
Determining whether MDxHealth ADR or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MDXH quote. (ISIN: BE0974461940)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.445
0.491
52 wk Range
0.400
5.330
Unusual Pre-Market activity
1/3
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.4450.491
52 wk Range
0.4005.330
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
MDXH Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
2.800
Upside
+506.06%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts do not anticipate the company will be profitable this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral
Analyst Ratings
4 Buy
2 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 2.800
(+506.06% Upside)
MDxHealth SA ADR Earnings Call Summary for Q2/2026
- MDxHealth Q2 2026 revenue hit $27.2M, beating estimates of $25.89M with 16% YoY growth and record 14% sequential increase despite Resolve UTI discontinuation.
- Company posted $0.18 loss per share vs. $0.17 estimate; gross margin compressed to 65.7% from 68.6% YoY due to product mix shift after ExoDx acquisition.
- Full-year 2026 revenue guidance set at $110M-$115M, implying 20%-26% growth; management targets positive adjusted EBITDA by year-end 2026.
- Pro forma cash position strengthened to $39.2M following $20M registered direct placement completed August 11, up from $19.2M at quarter-end.
- Shares surged 33% after-hours to $0.615 on strong revenue momentum, though stock remains down 83% over past year at $24M market cap.
Last Updated: 14/08/2026, 07:40 am
Read Full TranscriptEarnings
Latest Release
13/08/2026
EPS / Forecast
-0.18 / -0.17
Revenue / Forecast
27.21M / 25.89M
Compare MDXH to Peers and Sector
Metrics to compare | MDXH | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMDXHPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.7x | −22.9x | −0.4x | |
PEG Ratio | −0.02 | 0.81 | 0.00 | |
Price/Book | −1.2x | −6.3x | 2.6x | |
Price / LTM Sales | 0.2x | 18.1x | 3.1x | |
Upside (Analyst Target) | - | 27.7% | 48.4% | |
Fair Value Upside | Unlock | −2.3% | 6.5% | Unlock |
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company’s testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient’s previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient’s infection. It offers genomic prostate score, which provides personalized genomic insights to physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. The company sells its products through urology sales force consisting of direct sales representatives, strategic account managers, and regional sales managers. The company has a collaboration the initiation of Genomic Prostate Score (GPS) testing. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the MDxHealth ADR (MDXH) Stock Price Today?
The MDxHealth ADR stock price today is 0.462 USD.
What Stock Exchange Does MDxHealth ADR Trade On?
MDxHealth ADR is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for MDxHealth ADR?
The stock symbol for MDxHealth ADR is "MDXH."
What Is the MDxHealth ADR Market Cap?
As of today, MDxHealth ADR market cap is 23.730M USD.
What Is MDxHealth ADR's Earnings Per Share (TTM)?
The MDxHealth ADR EPS (TTM) is -0.652.
When Is the Next MDxHealth ADR Earnings Date?
MDxHealth ADR will release its next earnings report on 12/11/2026.
From a Technical Analysis Perspective, Is MDXH a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
How Many Times Has MDxHealth ADR Stock Split?
MDxHealth ADR has split 1 times.
How Many Employees Does MDxHealth ADR Have?
MDxHealth ADR has 364 employees.
What is the current trading status of MDxHealth ADR (MDXH)?
As of 14/08/2026, MDxHealth ADR (MDXH) is trading at a price of 0.462 USD, with a previous close of 0.462 USD. The stock has fluctuated within a day range of 0.445 USD to 0.491 USD, while its 52-week range spans from 0.400 USD to 5.330 USD.
What Is MDxHealth ADR (MDXH) Price Target According to Analysts?
The average 12-month price target for MDxHealth ADR is 2.800 USD, with a high estimate of 5 USD and a low estimate of 1 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +506.06% Upside potential.
What Is the MDXH Premarket Price?
MDXH's last pre-market stock price is 0.512 USD. The pre-market share volume is 4,100,000.000, and the stock has decreased by 0.050, or 10.820%.
What Is the MDXH After Hours Price?
MDXH's last after hours stock price is 0.517 USD, the stock has decreased by 0.055, or 11.900%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.